# Oral Epalrestat Therapy in Pediatric Subjects With PMM2-CDG

> **NCT04925960** · PHASE3 · TERMINATED · sponsor: **Maggie's Pearl, LLC** · enrollment: 42 (actual)

## Conditions studied

- Pmm2-CDG
- Phosphomannomutase 2 Deficiency
- Phosphomannomutase 2 Congenital Disorder of Glycosylation
- Phosphomannomutase II Congenital Disorder of Glycosylation
- Phosphomannomutase II Deficiency

## Interventions

- **DRUG:** Epalrestat
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04925960
- **Lead sponsor:** Maggie's Pearl, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-11-10
- **Primary completion:** 2025-02-28
- **Final completion:** 2025-02-28
- **Target enrollment:** 42 (ACTUAL)
- **Why stopped:** Due to futility
- **Last updated:** 2025-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04925960

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04925960, "Oral Epalrestat Therapy in Pediatric Subjects With PMM2-CDG". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT04925960. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*